{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:45:13Z","timestamp":1793256313853,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"21-22","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.drudis.2009.07.014","type":"journal-article","created":{"date-parts":[[2009,9,2]],"date-time":"2009-09-02T04:45:34Z","timestamp":1251866734000},"page":"1011-1020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":861,"title":["The impact of aromatic ring count on compound developability \u2013 are too many aromatic rings a liability in drug design?"],"prefix":"10.1016","volume":"14","author":[{"given":"Timothy J.","family":"Ritchie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.F.","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2009.07.014_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2009.07.014_bib2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2009.07.014_bib3","series-title":"Methods and Principles in Medicinal Chemistry","article-title":"Properties guiding drug- and lead-likeness","author":"Muresan","year":"2008"},{"key":"10.1016\/j.drudis.2009.07.014_bib4","unstructured":"Spotfire DXP 2.0 or DecisionSite 8.2.1"},{"key":"10.1016\/j.drudis.2009.07.014_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","article-title":"Drug-like properties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski","year":"2000","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.drudis.2009.07.014_bib6","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1021\/ci000403i","article-title":"Molecular complexity and its impact on the probability of finding leads for drug discovery","volume":"41","author":"Hann","year":"2001","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.drudis.2009.07.014_bib7","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1021\/jm021053p","article-title":"A comparison of physicochemical property profiles of development and marketed oral drugs","volume":"46","author":"Wenlock","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2009.07.014_bib8","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1023\/A:1012188625088","article-title":"Polar molecular surface properties predict the intestinal absorption of drugs in humans","volume":"14","author":"Palm","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2009.07.014_bib9","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2009.07.014_bib10","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1016\/j.bmcl.2008.07.071","article-title":"Physiochemical drug properties associated with in vivo toxicological outcomes","volume":"18","author":"Hughes","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2009.07.014_bib11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1021\/ci000338c","article-title":"Prediction of drug solubility by the general solubility equation (GSE)","volume":"41","author":"Ran","year":"2001","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.drudis.2009.07.014_bib12","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1021\/jm701407x","article-title":"Straightforward recursive partitioning model for discarding insoluble compounds in the drug discovery process","volume":"51","author":"Lamanna","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2009.07.014_bib13","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1002\/jps.10494","article-title":"Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol-water and immobilized artificial membrane lipophilicity","volume":"92","author":"Valko","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2009.07.014_bib14","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0026-895X(25)10691-3","article-title":"Characterization of two specific drug binding sites on human serum albumin","volume":"11","author":"Sudlow","year":"1975","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drudis.2009.07.014_bib15","first-page":"51","article-title":"The importance of plasma protein binding in drug discovery","volume":"2","author":"Trainor","year":"2007","journal-title":"EODC"},{"key":"10.1016\/j.drudis.2009.07.014_bib16","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S1359-6446(02)02412-1","article-title":"Substrate SAR in human p450s","volume":"7","author":"Lewis","year":"2002","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2009.07.014_bib17","first-page":"353","article-title":"Structure activity relationships for in vitro and in vivo toxicity","volume":"41","author":"Blagg","year":"2006","journal-title":"Annu. Rep. Med. Chem."},{"key":"10.1016\/j.drudis.2009.07.014_bib18","first-page":"369","article-title":"Importance of early assessment of bioactivation in drug discovery","volume":"41","author":"Hop","year":"2006","journal-title":"Annu. Rep. Med. Chem."},{"key":"10.1016\/j.drudis.2009.07.014_bib19","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1021\/jm060379l","article-title":"Medicinal chemistry of hERG optimizations: highlights and hang-ups","volume":"49","author":"Jamieson","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2009.07.014_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0079-6468(05)43007-6","article-title":"The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS","volume":"43","author":"Wood","year":"2005","journal-title":"Prog. Med. Chem."},{"key":"10.1016\/j.drudis.2009.07.014_bib21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.bmcl.2007.11.067","article-title":"From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis","volume":"18","author":"Santella","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2009.07.014_bib22","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bmcl.2007.11.087","article-title":"From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part II: acyclic replacements for the (3S)-3-benzylpiperidine in a series of potent CCR3 antagonists","volume":"18","author":"Gardner","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2009.07.014_bib23","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1021\/jm049717d","article-title":"Time-related differences in the physical property profiles of oral drugs","volume":"47","author":"Leeson","year":"2004","journal-title":"J. Med. Chem."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644609002785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644609002785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:05:27Z","timestamp":1761221127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644609002785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":23,"journal-issue":{"issue":"21-22","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S1359644609002785"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2009.07.014","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1165098.627997","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.1165098.628351","asserted-by":"object"}]},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of aromatic ring count on compound developability \u2013 are too many aromatic rings a liability in drug design?","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2009.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}